-
公开(公告)号:US20220211797A1
公开(公告)日:2022-07-07
申请号:US17392724
申请日:2021-08-03
Applicant: GENENTECH, INC.
Inventor: Frederick COHEN , Lewis J. GAZZARD , Vickie Hsiao-Wei TSUI , John A. FLYGARE
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
-
公开(公告)号:US20160102119A1
公开(公告)日:2016-04-14
申请号:US14974140
申请日:2015-12-18
Applicant: GENENTECH, INC.
Inventor: Frederick COHEN , Lewis J. GAZZARD , Vickie Hsiao-Wei TSUI , John A. FLYGARE
IPC: C07K5/087
CPC classification number: A61K38/06 , A61K38/00 , A61K45/06 , C07K5/08 , C07K5/0804 , C07K5/0806 , C07K5/0812 , C07K5/0815
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Abstract translation: 可用作治疗恶性肿瘤的治疗剂的具有通式I的IAP的新型抑制剂:其中R1,R2,R3,R4,R5和R6如本文所述。
-
公开(公告)号:US20140294868A1
公开(公告)日:2014-10-02
申请号:US14208374
申请日:2014-03-13
Applicant: GENENTECH, INC. , SPIROGEN SÀRL
Inventor: Philip Wilson HOWARD , John A. FLYGARE , Thomas PILLOW , Binqing WEI
IPC: A61K47/48 , C07D487/04 , A61K31/5517
CPC classification number: A61K47/6869 , A61K31/5517 , A61K47/6803 , A61K47/6851 , A61K47/6855 , A61K47/6889 , A61P35/00 , C07D487/04 , C07D487/16 , C07D519/00
Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US20140235551A1
公开(公告)日:2014-08-21
申请号:US14269739
申请日:2014-05-05
Applicant: Genentech, Inc.
Inventor: Frederick COHEN , Lewis J. GAZZARD , Vickie Hsiao-Wei TSUI , John A. FLYGARE
IPC: C07K5/08
CPC classification number: A61K38/06 , A61K38/00 , A61K45/06 , C07K5/08 , C07K5/0804 , C07K5/0806 , C07K5/0812 , C07K5/0815
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Abstract translation: 可用作治疗恶性肿瘤的治疗剂并具有通式I的IAP的新型抑制剂:其中R1,R2,R3,R4,R5和R6如本文所述。
-
公开(公告)号:US20130143824A1
公开(公告)日:2013-06-06
申请号:US13654307
申请日:2012-10-17
Applicant: Genentech, Inc.
Inventor: Kurt Deshayes , Wayne J. FAIRBROTHER , John A. FLYGARE , Matthew C. FRANKLIN , Saloumeh FISCHER , Domagoj VUCIC
IPC: A61K38/08
CPC classification number: A61K38/08 , A61K38/00 , C07K7/08 , C07K14/001 , C07K14/4747 , C07K2319/00
Abstract: The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.
Abstract translation: 本发明涉及用于增强哺乳动物细胞凋亡的物质组合物,以及使用这些物质组合物的方法。
-
公开(公告)号:US20180125997A1
公开(公告)日:2018-05-10
申请号:US15786055
申请日:2017-10-17
Applicant: MedImmune Limited , Genentech, Inc.
Inventor: Philip Wilson HOWARD , John A. FLYGARE , Thomas PILLOW , Binqing WEI
IPC: C07D519/00 , C07D487/16 , A61K31/5517
Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 43; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R16, R17, R19, R20, R21 and R22 are as defined for R6, R7, R9, R10, R11 and R2 respectively; wherein Z is CH or N; wherein T and T′ are independently selected from a single bond or a C1-9 alkylene, which chain may be interrupted by one or more heteroatoms e.g. O, S, N(H), NMe, provided that the number of atoms in the shortest chain of atoms between X and X′ is 3 to 12 atoms; and X and X′ are independently selected from O, S and N(H).
-
公开(公告)号:US20170136084A1
公开(公告)日:2017-05-18
申请号:US15420817
申请日:2017-01-31
Applicant: GENENTECH, INC.
Inventor: Frederick COHEN , Lewis J. GAZZARD , Vickie Hsiao-Wei TSUI , John A. FLYGARE
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
-
公开(公告)号:US20140080805A1
公开(公告)日:2014-03-20
申请号:US14088110
申请日:2013-11-22
Applicant: Genentech, Inc.
Inventor: Frederick COHEN , Vickie Hsiao-Wei TSUI , Cuong LY , John A. FLYGARE
IPC: C07D471/04 , C07D417/14 , C07D417/04
CPC classification number: C07D471/04 , C07D417/04 , C07D417/14
Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4′, R5, R6 and R6′ are as described herein.
Abstract translation: 本发明提供了可用作治疗恶性肿瘤的治疗剂的新的IAP抑制剂,其中化合物具有通式I:其中A,Q,X 1,X 2,Y,R 1,R 2,R 3,R 4,R 4',R 5,R 6 和R6'如本文所述。
-
-
-
-
-
-
-